127253-06-9

Usage

Uses

Used in Pharmaceutical Industry:
Clarithromycin Oxime is used as an impurity in the production of Clarithromycin, a macrolide antibiotic. It is important to monitor and control the levels of this impurity to ensure the quality, safety, and efficacy of the final drug product. The presence of Clarithromycin Oxime can impact the pharmacological properties and therapeutic effects of Clarithromycin, making it a critical parameter to consider during the drug development and manufacturing process.

Upstream product

• 50-00-0 formaldehyd 
• 101666-67-5 6-O-methyl-N-demethylerythromycin A 9-oxime 
• 101666-16-4 C₅₂H₇₈N₂O₁₇ 
• 101666-16-4 C₅₂H₇₈N₂O₁₇ 
• 81103-09-5 2'-O,3'-N-bis(benzyloxycarbonyl)-N-demethylerythromycin A 
• 103450-87-9 3-O-descladinosyl-9-oxime clarithromycin 
• 81103-11-9 clarithromycin 
• 101666-32-4 C₅₉H₈₄N₂O₁₇ 
• 101670-80-8 C₆₀H₈₆N₂O₁₇ 

Downstream Products

• 127253-05-8 6-O-Me Ery A 9(Z)-oxime 
• 1289429-85-1 C₄₅H₇₈N₂O₁₂ 
• 1289429-90-8 C₄₆H₇₉N₃O₁₃ 
• 1236808-96-0 3'-N-demethyl-2'-O-3'-N-di-{[(phenylmethyl)oxy]carbonyl}-6-O-methyl-9a-aza-9a-homoerythromycin A 
• 1236808-99-3 3'-N-demethyl-4-O-(2-diethylaminoethanoyl)-2'-O-3'-N-di-{[(phenylmethyl)oxy]carbonyl}-6-O-methyl-9a-aza-9a-homoerythromycin A 

Relevant academic research and scientific papers

Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides

A practicable method of introducing a side chain to the C-4′ position of 5-O-desosamine in the 14-membered ketolides was developed. And using this method, a series of novel modified 5-O-mycaminose ketolides were synthesized. These ketolides containing 5-O

SUBSTANTIALLY PURE CLARITHROMYCIN 9-OXIME AND ITS PREPARATION THEREOF

The present invention relates to substantially pure Clarithromycin 9-oxime more particularly Clarithromycin 9(E)-oxime having purity more than 98% and corresponding (Z)-isomer not more than 1%. The present invention further relates to a process for preparation of Clarithromycin 9(E)-oxime of formula (I), its pharmaceutically acceptable salts and purification.

Chemistry and biology of macrolide antiparasitic agents

Macrolide antibacterial agents inhibit parasite proliferation by targeting the apicoplast ribosome. Motivated by the long-term goal of identifying antiparasitic macrolides that lack antibacterial activity, we have systematically analyzed the structure-activity relationships among erythromycin analogues and have also investigated the mechanism of action of selected compounds. Two lead compounds, N-benzylazithromycin (11) and N-phenylpropylazithromycin (30), were identified with significantly higher antiparasitic activity and lower antibacterial activity than erythromycin or azithromycin. Molecular modeling based on the cocrystal structure of azithromycin bound to the bacterial ribosome suggested that a substituent at the N-9 position of desmethylazithromycin could improve selectivity because of species-specific interactions with the ribosomal L22 protein. Like other macrolides, these lead compounds display a strong "delayed death phenotype"; however, their early effects on T. gondii replication are more pronounced.

PROCESS FOR THE PREPARATION OF 6-O-METHYLERYTHROMYCIN A 9-OXIME

The present invention relates to process for the preparation of 6-O-methylerythromycin A 9-oxime by treating 6-O-methylerythromycin A with hydroxyl amine hydrochloride in the presence of a base and a solvent.

Ketolides from the class of 15-membered lactams

The present invention relates to the new 15-membered ketoazalides from the class of 6-O-methyl-8a-aza-8a-homo-and 6-O-methyl-9a-aza-9a-homoerythromycin A with the general formula (I) wherein A represents NH group and B at the same time represents C=O group, or A represents C=O group and B at the same time represents NH group, R1 represents OH group, L-cladinosyl group of the formula (II) or together with R2 represents ketone, R2 represents hydrogen or together with R1 represents ketone, R3 represents hydrogen or C1-C4alkanoyl group, to intermediates and a process for their preparation, to their pharmaceutically acceptable addition salts with inorganic or organic acids, to the process for the preparation of pharmaceutical compositions, as well as to the use of pharmaceutical compositions for treating bacterial infections.

CHEMICAL MODIFICATION OF ERYTHROMYCINS. VIII. A NEW EFFECTIVE ROUTE TO CLARITHROMYCIN (6-O-METHYLERYTHROMYCIN A)

Selective O-methylation of the C-6 hydroxyl group of erythromycin A could be satisfactorily achieved by using its 9-oxime derivatives as the starting materials.Thus, 6-O-methylerythromycin A (clarithromycin) was synthesized from 2'-O-,3'-N-bis(benzyloxycarbonyl)-N-demethylerythromycin A via its 9-oxime derivative by 6 steps.